PCSK9 inhibitors × lipids

TrialJAMA cardiology2017

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.

Robert P Giugliano et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 7,533 people · 2017

Randomised comparison

Lowered lipids

−14%−21% to −8%

Bigger than 3 in 10 on the map

As reported

HR 0.86, 95% CI 0.79–0.92

Range includes no effect

No clear effect on lipids

−20%−40% to +7%

Bigger than 4 in 10 on the map

As reported

HR 0.80, 95% CI 0.60–1.07

Two numbers in the abstract

the abstract, start to end

the primary endpoint (hazard ratio [HR], 0.80; 95% CI, 0.60-1.07) to a similar degree as in the 25 529 patients who had baseline LDL-C of at least 70 mg/dL (HR 0.86; 95% CI, 0.79-0.92; P = .65 for

← favours treatmentfavours comparator →
could be chance
Lipids
HR 0.800.60–1.07
Lipids
HR 0.860.79–0.92
PCSK9 inhibitorsLipids

PCSK9 inhibitors × lipidshelps?settled

unlikelylikely
0.930.93 without it
1 / 4

37 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 29117276